LDS/Medical Tests/HOXB13 (G84E) Gene Mutation Analysis

HOXB13 (G84E) Gene Mutation Analysis

HOXB13 belongs to the homeobox protein (HOX) gene family which encode various transcription factors. There are 39 HOX genes divided into 4 clusters: A, B, C, and D. HOXB13 is located on the long arm of chromosome 17 (17q21.32) and is composed of 284 amino acids. It consists of a homeoprotein domain coding for a specific homeoprotein (60 amino acids), that binds to DNA and regulates transcription and translation. The MEIS1 interaction domain regulates the binding of the homeoprotein to DNA. HOXB13 is proven to be a key regulator of differentiation and development of the prostate gland and has also been shown to have tumor suppressing activity. Mutations in the HOXB13 gene are associated with the development of prostate cancer.

The mutant variant G84E, which was identified in 2012, is associated with the development of prostate cancer. It involves a substitution of adenine for guanine in the second position of codon 84 resulting in the substitution of glutamic acid for glycine in the homeoprotein. The exact oncogenic mechanism of HOXB13 in the prostate gland is not clearly understood, however, most of the mutations in HOXB13 impact the MEIS1 interacting domain This may affect the DNA binding ability of the homeoprotein resulting in dysregulated transcription and poor tumor suppression. Nearly 60% of the carriers of G84E mutation develop prostatic cancer by the age of 80.

Prostatic cancer comes within the top 5 most prevalent cancers in men globally and the second most leading cause of cancer-related deaths in men. Germline mutations account for 10 -12% of prostatic cancer. It must be noted that the detection of pathogenic variants in HOXB13 alone doesn’t establish the diagnosis of prostate cancer and the absence of the gene doesn’t essentially rule out prostate cancer. HOXB13 is not used for screening except in relatives of individuals with a known mutation. But is usually tested for as part of the genetic mutation panel for prostate cancer.

  • As an aids in diagnosing hereditary prostate cancer
  • Evaluating patients with familial history of prostate cancer

Positive: Presence of G84E variant in the HOXB13 gene.

Negative: Absence of G84E variant in the HOX gene. A negative finding however cannot rule out the diagnosis of prostate cancer. Presence of other variants in the same or different gene must be accessed.

Negative for mutations analyzed (No mutations or pathogenic variants in the HOXB13 gene were detected).

Variant detection using Next Generation Sequencing (NGS), Sanger sequencing, sequence capture assay, Multiplex-Ligation Dependent Probe Amplification (MLPA), and Allele specific primer extension by Real-time PCR (ARMS).

Whole blood (preferred), Saliva. Container: Lavender (EDTA) or Yellow (ACD), sterile container for saliva.

Stability Whole blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
BRCA 1, BRCA 2, ATM, CHEK2, PALB2, FOXA1, AR and RFX6 gene mutation analysis, Prostate-Specific Antigen (PSA), percentage free PSA, PSA velocity, Prostate Cancer Antigen 3 (PCA 3), Prostate Health Index (PHI), Prostate Acid Phosphatase (PAP), Kallikrein-Related Peptidase 3 (KRP 3), PCA3/KRP3 ratio, prostate secretion culture, prostate biopsy, and complete blood count.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login